Network Security Internet Technology Development Database Servers Mobile Phone Android Software Apple Software Computer Software News IT Information

In addition to Weibo, there is also WeChat

Please pay attention

WeChat public account

Shulou

Us lawmakers questioned the safety of Musk Neuralink and asked SEC to investigate its securities fraud.

2025-01-28 Update From: SLTechnology News&Howtos shulou NAV: SLTechnology News&Howtos > IT Information >

Share

Shulou(Shulou.com)11/24 Report--

CTOnews.com, Nov. 22 (Reuters)-four U.S. lawmakers have asked SEC to investigate whether billionaire Musk committed securities fraud by misleading investors about the security of brain implants developed by his company Neuralink, according to a letter sent to the Securities and Exchange Commission (SEC) on Tuesday.

Those who asked for the investigation were Representative Blumenard, Democrat of Oregon, McGovern of Massachusetts, and Lee and Cardenas of California. It is worth mentioning that Neuralink is preparing for its first clinical trial in humans.

The letter cited veterinary records from Neuralink's experiments on monkeys, showing that the animals suffered "serious health effects" as a result of the implants, including paralysis, epilepsy and brain swelling. At least 12 young and healthy monkeys were euthanized because of "problems with the company's implants," the letter said, while Neuralink chief executive Musk played down investors' concerns about animal test results.

CTOnews.com noted that Musk wrote in an article on his social media site X on Sept. 10 that "not a single monkey died because of the Neuralink implant."

In a letter to SEC, Blumenard and other lawmakers said they reviewed evidence that the deaths of animals in Neuralink experiments were "directly related to the safety and marketability of Neuralink's brain-computer interface." As a result, Musk's statement "may have violated" SEC rules because he denied the connection.

In May, Neuralink announced that it had received approval for FDA's first human clinical trial, but gave no details of the planned study.

Welcome to subscribe "Shulou Technology Information " to get latest news, interesting things and hot topics in the IT industry, and controls the hottest and latest Internet news, technology news and IT industry trends.

Views: 0

*The comments in the above article only represent the author's personal views and do not represent the views and positions of this website. If you have more insights, please feel free to contribute and share.

Share To

IT Information

Wechat

© 2024 shulou.com SLNews company. All rights reserved.

12
Report